Dr. James (Jim) Woody, CEO of 180 Life Sciences Corp., a newly formed clinical-stage biotech company focused on novel drugs for unmet needs in inflammatory diseases, fibrosis, and pain, discusses three clinical programs using anti-TNF, with the lead program in Phase 2b/3 for Dupuytren’s contracture, a fibrotic disease of the hand. He previously led the team responsible for developing Remicade, the first of the TNF inhibitor biologics.
Dr. James Woody is Chief Executive Officer at 180 Life Sciences Corp., a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. Dr. Woody has more than 25 years of pharmaceutical research and management expertise. He currently serves as Chairman of Oncomed Pharmaceuticals, where he was previously a founder and CEO, and General Partner at Latterell Venture Partners, a venture capital group focusing on early-stage healthcare companies. Dr. Woody has served in a variety of health and management roles, including as President of Roche Bioscience and CSO and Senior Vice President of R&D for Centocor. He also served as Commanding Officer and Director at the U.S. Naval Medical Research and Development Command in Bethesda, Maryland. Dr. Woody earned his M.D. from Loma Linda University and his Ph.D. in Immunology from the University of London.